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Edited by Hans EklundAbstract The sequences contributing to the catalytic site of
protein kinases are not all comprised within the highly conserved
catalytic core. Thus, in mammalian cAMP-dependent protein
kinase (PKA), the C-terminal sequence participates in substrate
binding. Using synthetic peptides mimicking the FxxF motif
present at most C-termini of AGC kinases, we have raised highly
speciﬁc antibodies which are potent and speciﬁc inhibitors of the
catalytic activity of the cognate protein kinase. Taking into
account the structure of PKA, these results point to the potential
of the C-terminal region of protein kinases as a target for
designing speciﬁc protein kinase inhibitors.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein phosphorylation by protein kinases serves as a uni-
versal molecular switch participating in the control of almost
every cellular process [1]. Impaired function of protein kinases
has been implicated in many diseases [2,3] and in the patho-
genenicity of microorganisms and parasites [4,5]. Thus, in-
tensive eﬀorts are carried out in search for protein kinase
speciﬁc inhibitors [6].
The high degree of sequence and structure conservation of
the eukaryotic protein kinase catalytic core [7,8] makes it dif-
ﬁcult to obtain inhibitory compounds able to discriminate
between diﬀerent kinases, in particular between isoforms
within a single species or between counterparts of the same
kinase in diﬀerent species [9]. In contrast to the conserved 30-
kDa catalytic core, the N- and C-terminal extensions of pro-
tein kinases greatly vary in size and sequence, encoding a large
variety of domains implicated in activity regulation and in the
binding to other proteins or nucleic acids [10].
The C-terminal extension of cAMP-dependent protein ki-
nase catalytic subunit (PKA) participates in the structural
changes involved in the transition from the open to the closed
conformation of the protein [11], and is important for catalytic* Corresponding author. Fax: +33-1-45-68-83-99.
E-mail address: traincar@pasteur.fr (F. Traincard).
Abbreviations: PKA, cAMP-dependent protein kinase catalytic sub-
unit; PKG, cGMP-dependent protein kinase; PBS, phosphate-buﬀered
saline; WB, Western blot; AA, amino acid; Dd, Dictyostelium
discoideum; Pf, Plasmodium falciparum
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E334) of bovine PKA (Fig. 1A), is implicated in substrate
binding [12]. In addition, the cleavage of bovine PKA between
Glu 332 and Glu 333 leads to kinase inactivation [13], and a
single PheﬁAla substitution in the 647FxxF-COOH motif
lying at the extreme C-terminus of Dictyostelium PKA results
in an important loss in enzyme activity and in decrease of
protein stability [14].
Based on these observations, we have hypothesized that the
C-terminal end of protein kinases could be a target for de-
signing speciﬁc inhibitors. Here, we report the inhibitory
properties of antibodies directed against peptides mimicking
the last amino acids (AAs) of two diﬀerent PKAs and of one
cGMP-dependent protein kinase (PKG).2. Materials and methods
2.1. Antibodies
Synthetic peptides corresponding to the sequences F126-Q137 and
S637-F650 (peptide S) of Dictyostelium discoideum (Dd) PKA, and to
A311-W325 of Plasmodium falciparum (Pf) PKA (Fig. 1) synthesized
with a cysteine added at their C-terminus were coupled to BSA (FV,
Boehringer Mannheim) by glutaraldehyde or 3-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS) according to Schaaper et al. [15].
Rabbits were injected 3 times at one month intervals by subcutaneous
injections of a mixture of 250 lg glutaraldehyde and 250 lg MBS-
conjugated BSA-peptide, and 125 lg of free peptide in complete (ﬁrst
injection) or incomplete Freund’s adjuvant. Final bleeding was per-
formed after an additional booster injection in incomplete Freund’s
adjuvant 10 days before bleeding. Dd PKA peptides were coupled to
Epoxy Activated Sepharose 6B in neutral or basic conditions accord-
ing to the manufacturer’s protocol (Pharmacia Biotech). Seric anti-
bodies, eluted by glycine buﬀer, pH 2.3, were isolated by aﬃnity
chromatography in a column containing a 1/1 mix of neutral pH/basic
pH peptide coupled resins. Antibodies against peptide S and against
peptide F126-Q137 of Dd PKA are, respectively, called anti-Dd PKA-
Ct and anti-Dd PKA-Nt antibodies. Crude rabbit anti-Pf PKA-Ct sera
were used in the experiments. The antibodies against the C-terminus of
human PKAa (anti-hu PKA-Ct) were from Santa-Cruz (PKAacat
(C20)), and those against the C-terminal peptide D657-F671 (peptide
G) of human PKGIa (anti-PKG-Ct) or against PKCe (721–737) were
from Calbiochem. Note that the C-terminal peptide sequences are
identical in bovine and in human PKGIa.
2.2. Proteins and peptides
Recombinant Dictyostelium C309 PKA (des-(1–308)-C in [14]) and
PKA from 16 h developed Dd cells were, respectively, obtained as
described in [14,16]. Bovine PKAa was from Sigma and porcine PKAa
was from ICN. Activated MAP Kinase ERK2 (rat), PKGIa (bovine)
and PKCe (human) were from Calbiochem. Human PKAa C-terminal
peptide was from Santa-Cruz and human PKGIa C-terminal peptide
was from Calbiochem. Histone H2B was from Roche. The speciﬁcblished by Elsevier B.V. All rights reserved.
Fig. 1. The C-terminus of protein kinases. (A) Sequence alignment of AGC protein kinase C-terminal extensions. The sequence starts with the ﬁrst
residue (numbered at left) after helix aJ of the catalytic core [7]. *: Sequence continuation. Roman numbers at right of the sequences refer to the AGC
sub-group of the corresponding protein. Aromatic residues of FxxF or WxxxF motifs are in bold. Sequences of the immunogen peptides are un-
derlined. (B) Sequence alignment of the 23 last amino acids of the C-terminal extension of PKAs. Amino acids identical to mouse PKAa are indicated
by (–). (C) Ribbon structure of mouse PKAa protein (1ATP). The C-terminal extension (starting at K310) is shown in light gray. The counterpart of
the Dd PKA peptide used as immunogen (V337-F350) is shown in dark gray. Side chains of F347 and F350 are shown in light gray. Structure drawn
with Swiss Pd. viewer 3.7. Abbreviations: PKC: Protein kinase C; RAC: proto-oncogenic protein kinase; bARK: b-Adrenergic Receptor Kinase;
S6K: S6 kinase; DBF2: Cell cycle protein kinase; Sgk: Serum/glucocorticoid-regulated kinase.
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spectively, 40, 53, and 41 pmol ATP transferred to substrate peptide/
min/lg of protein.2.3. Protein kinase activity measurement
Dd PKA activity was measured in 10 lg Dd cell extracts by [32P]
incorporation into Kemptide for 30 min at 30 C as described [16],
using 0.05 M Tris–HCl buﬀer, pH 7.0, instead of MOPS, in the pres-
ence of 100 lM cAMP and 10 lg/ml BSA in the absence or presence of
PKI (400 lM). Autophosphorylation of C309 (250 ng) was performed
for 15 min at room temperature. PKA was then subjected to electro-
phoresis on a 10% polyacrylamide gel and the protein was transferred
to a nitrocellulose membrane (Schleicher & Schuell, BA83) for auto-
radiography. Mammalian PKA activity was measured like Dd PKA
activity except that 12 lM ATP was used. PKGIa activity was mea-
sured by [32P] incorporation into Glasstide in 25 ll of 20 mM Tris–HCl
buﬀer, pH 7.5, 10 mM Mg2þ-acetate, 10 mM NaF, 10 mM DTT, 0.2
mg/ml BSA, containing 200 lM [c-32P]ATP (200–500 cpm/pmol) and
100 lM Glasstide (Calbiochem), in the presence of 10 lM cGMP (30
min at 30 C). For [32P] phosphorylation of Histone H2B by PKGIa, 2
lg Histone H2B replaced Glasstide and incubation was performed at
30 C for 1.5 h. Histone was then chromatographed on a 15% poly-
acrylamide gel and transferred to a nitrocellulose membrane for
autoradiography.
2.4. ELISA and Western blot
Microtiter plates were coated with protein kinases or peptides at 0.5
or 1 lg/ml in phosphate-buﬀered saline (PBS). All washes were per-
formed with 0.1% Tween 20 containing PBS (PBST) and antibody
dilutions were done in 1% BSA containing PBST. Serial antibody di-
lutions were incubated in the wells (2 h at 37 C) followed by perox-
idase-labeled anti-rabbit IgG (H+L) goat antibodies diluted 1/2000
(Vector laboratories) (1 h at 37 C), and ﬁnally by OPD/H202 substratesolution before reading at 490 nm. Avidities of the antibodies were
measured as described [17] in at least two diﬀerent experiments.
Protein kinase samples (10 ng for testing with speciﬁc antibody or 1
lg for testing with heterologous antibody) were loaded onto 7.5% or
10% polyacrylamide gels and Western blotted as in [16] using anti-Dd
PKA-Ct antibodies (500 ng/ml), anti-hu PKA-Ct antibodies (200 ng/
ml) or anti-PKG-Ct antibodies (1 lg/ml).3. Results
3.1. Speciﬁc anti-peptide antibodies against native protein
kinases
Fig. 1A shows the alignment of sequences lying immediately
downstream of the catalytic core of 10 kinases belonging to the
9 sub-groups of AGC protein kinases [7]. The conservation is
low in this region, even between PKAs of pathogens and their
human host (Fig. 1B). As shown in Fig. 1A and B, FxxF or
WxxxF motifs (C-ter motif) are found in almost all sequences,
although not always at their very C-terminal end.
We have used rabbit antibodies against synthetic peptides
(Fig. 1) containing the C-ter motif of PKA from Dd and Pf, as
well as from human PKA and PKGIa. The antibody reactivity
was tested either in ELISA using synthetic peptides (sp) or in
ELISA and Western blot (WB) using recombinant protein (P)
(Fig. 2). Anti-Dd PKA-Ct antibodies did not bind peptides
from human PKAa or from PKGIa in ELISA (Fig. 2A); they
did not recognize porcine PKA and PKGIa proteins in WB
contrary to Dd PKA (Fig. 2A, inset). The anti-Dd PKA-Ct
Fig. 2. Antibodies reactivity with protein kinases and peptides. (A) Anti-Dd PKA-Ct antibodies. ELISA of the anti-Dd PKA antibodies with Dd PKA
(d), human PKAa (j), and PKGIa (m) synthetic peptides. Inset: WB detection of Dd PKA (1), porcine PKA (2) and PKGIa (3) by anti-Dd PKA-Ct
antibodies (a) and by antibodies directed against human PKA (2b) or PKGIa (3b). Table: Avidity of the anti-Dd PKA antibodies for the immunogen
peptide S and for peptides SN and Sm. (B) Anti-PKG-Ct antibodies. ELISA of the anti-PKGIa antibodies with PKGIa (m), Dd PKA (d) and PKCe
(n) protein. Inset: WB detection of PKGIa (1), porcine PKA (2) and Dd PKA (3) by the anti-PKG-Ct antibodies (a) and by antibodies directed
against human PKA (2b) or Dd PKA (3b). Table: Avidity of the anti-PKG antibodies for the immunogen peptide G and for peptides GC and GCm.
Fig. 3. Inhibition of protein kinase activity by C-ter antibodies. (A)Dictyostelium PKA. PKA activity of Dd extracts preincubated with anti-Dd PKA-
Ct (d) or -Nt antibodies (s). Histogram: PKA activity in Dd extracts in the absence (white box) or in the presence of PKI (black box). Inset:
Autophosphorylation of Dd PKA in the absence of antibody (a) or in the presence of a control antibody (b), anti-Dd PKA-Ct antibody (c) or PKI
(d). (B) Porcine PKAa. Porcine PKAa activity after preincubation with anti-hu PKA-Ct (d) or control (s) antibodies. (C) Bovine PKGIa. PKGIa
activity after preincubation with anti-PKG-Ct (d) or control (s) antibodies. Inset: Histone H2B phosphorylation by PKGIa alone (a) or by PKGIa
preincubated with control (b) or anti-PKG-Ct (c) antibodies. The results presented were obtained in one of at least two experiments giving similar
results. Kinase activities are expressed as pmol of ATP per min in 10 ll of reaction mixture.
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(sp), Erk2 (P), or yeast PKA2 (P), despite its extensive se-
quence similarity with Dd PKA (data not shown). Deletion of
the C-terminal part of peptide S abolished anti-Dd PKA-Ct
antibody binding to the corresponding SN peptide. Similarly,
binding to the mutated peptide Sm was very poor
(KD >2 106 M) as compared to peptide S (KD¼ 5.0
0.05 1011 M) (Fig. 2A, Table). The anti-PKG-Ct antibodies
were reactive with recombinant PKGIa, but not with porcine
PKA and PKCe in ELISA (Fig. 2B). In WB, they reacted with
recombinant PKGIa but not with porcine PKA and Dd PKA
(Fig. 2B, inset). These antibodies did not crossreact with Pf
PKA (sp), Erk1 (sp), Erk2 (P) and yeast PKA2 (P) in ELISA
or in WB (not shown). The anti-PKG-Ct antibodies bound the
GC peptide with the same aﬃnity as the immunogen peptide
G, while the GCm peptide bound very poorly (KD>2 106
M) (Fig. 2B, Table). The anti-hu PKA-Ct and the anti-Pf
PKA-Ct antibodies were reactive, respectively, with mamma-
lian PKA and Pf PKA, but not with any of the other protein
kinases or peptides tested (not shown).
In summary, antibodies against peptides from the C-termi-
nus of PKA and PKG bind speciﬁcally the cognate kinases
with high speciﬁcity, and aromatic amino acids from their
conserved C-ter motif are strong epitope determinants.
3.2. Antibodies directed against the C-terminus of PKA and
PKG inhibit their catalytic activity
As shown in Fig. 3A, pre-incubation of cellular Dd PKA
with anti-Dd PKA-Ct antibodies, but not with anti-Dd PKA-
Nt antibodies, resulted in a strong inhibition of PKA activity,
which was dependent on antibody concentration. The phos-
phorylating activity in the extract was almost 100% inhibited
by PKI, demonstrating that it was due to PKA (Fig. 3A, his-
togram). Using C309 recombinant protein, we obtained a 95%
inhibition of Kemptide phosphorylation for a ratio of 2 anti-
gen binding sites/epitope (not shown). Dd PKA autophos-
phorylation is strongly reduced in the presence of the C-ter
antibodies (Fig. 3A, inset, lane c) but not by anti-Dd PKA-Nt
antibodies (lane b). While the anti-hu PKA-Ct antibodies
speciﬁcally inhibited porcine PKA activity by 65% (Fig. 3B),
the anti-PKG-Ct antibodies inhibited totally and speciﬁcally
the kinase activity for an antigen binding site/epitope ratio of 5
(Fig. 3C), as well as Histone 2B phosphorylation (Fig. 3C,
inset). The inhibition of the kinases was completely reversed
upon pre-incubation of the speciﬁc antibodies with their im-
munogen peptide (not shown).4. Discussion
We have raised antibodies against synthetic peptides con-
taining an FxxF or a WxxxF motif from protein kinases. The
high speciﬁcity of these reagents is indicated by the fact that they
were able to diﬀerentiate kinase counterparts belonging to dif-
ferent phyla like PKA from mammals and from P. falciparum.
Despite the fact that they were obtained against synthetic pep-
tides, the antibodies displayed good aﬃnities for the native
proteins (2.5 0.1 109 M for Dd-PKA, 3.0 1.5 108 M
for porcine PKAa, and 5.0 0.15 109 M for PKGIa). They
strongly inhibited Dd PKA, PKGIa, and mammalian PKAa
activity as well as PKA autophosphorylation and Histone H2B
phosphorylation by PKG (Fig. 3). The epitopes of the anti-DdPKA-Ct andof the anti-PKG-Ct antibodies are located in theC-
terminal part of their immunogenpeptides, sincemutation of the
aromatic residues of the C-ter motif strongly reduced antibody
binding (Fig. 2, Tables).
The involvement of the Phe from the FxxF C-terminal motif
of PKA in antibody binding provides a clue for their inhibitory
eﬀect. Indeed, the structure of mouse PKA shows that Phe 347
and Phe 350 are buried in the small lobe of the catalytic core
with Phe 350 docked in a deep hydrophobic pocket ([12],
Fig. 1C). We propose that binding of the antibodies to PKA or
PKG results in movement of the terminal Phe residues out of
their hydrophobic environment, leading to a destabilization of
the interaction of the C-terminal domain with the catalytic
domain and/or to a destabilization of the catalytic domain it-
self. An activating allosteric transition has been proposed for
the AGC kinase PDK1 upon docking of a peptide into a
similar hydrophobic pocket [18].
Several lines of evidence indicate that substrate-binding in-
hibition is not due to steric hindrance by the antibodies. In-
deed, antibodies raised against peptide 721–737 containing the
728FSYF731 C-ter motif from PKCe bound human PKCe with
a high KD (6.0 1.0 1010 M), but did not inhibit its catalytic
activity (not shown). Possibly, these antibodies did not inhibit
the kinase because they did not bind the FSYF motif itself
which is not at the C-terminus of the peptide, but surrounding
regions. Regardless, they bound PKCe in a position very close
to the one occupied by anti-PKA and PKGIa antibodies on
their respective kinases without impeding substrate binding. In
addition, the KD of the anti-Dd PKA-Ct antibodies for Dd
PKA is unchanged in the presence of mM concentrations of
the substrate-like PKI peptide (not shown). Note that small
peptides were used as PKA or PKG substrates (5 AA for
Kemptide, 7 AA for Glasstide as compared to 16 AA for the
substrate peptide of PKC and 20 AA for PKI). In conclusion,
our results are in favor of an inhibition of the kinase catalytic
activity by antibody-induced conformational changes.
We suggest that species-speciﬁc antibodies will be obtained
against the C-ter motif sequence lying immediately down-
stream from the catalytic core in many other protein kinases.
Such antibodies are likely to be potent phosphotransfer in-
hibitors in those kinases where the C-terminal extension is
implicated in substrate binding, but possibly also when the C-
terminal extension contributes to the speciﬁcity and activity
regulation [19,20]. Finally, our results more generally under-
line the variable C-terminal extension of some protein kinases
as a new target for designing speciﬁc inhibitors.
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